jamesbenet/Getty
Prostate cancer is 60 per cent more common in African Americans than in Caucasians, and black Americans are twice as likely to die from the disease when they get it. Yet black men are less likely to be included in clinical trials of drugs for the disease – and accidental biases against their biology seem to be partly to blame.
Speaking at a meeting of the American Society for Clinical Oncology in Chicago this month, Susan Halabi, of Duke University, says her team found that only 12 per cent of the participants in phase 3 clinical trials – the type of…
